floxuridine has been researched along with Minimal Disease, Residual in 3 studies
Floxuridine: An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
floxuridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-fluorouracil as the nucleobase; used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this series confined to patients with minimal residual disease after initial therapy subjected to second-line intraperitoneal treatment, it appears to identify a poor prognostic (positive) subset for survival." | 2.70 | Correlation of p53 immunostaining in primary and residual ovarian cancer at the time of positive second-look laparotomy and its prognostic role: a Southwest Oncology Group ancillary study. ( Alberts, DS; Belt, RJ; Cote, R; Felix, J; Hawes, D; Liu, PY; Muggia, FM; Terada, K; Wilczynski, S, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hawes, D | 1 |
| Liu, PY | 2 |
| Muggia, FM | 2 |
| Wilczynski, S | 1 |
| Cote, R | 1 |
| Felix, J | 1 |
| Terada, K | 1 |
| Belt, RJ | 1 |
| Alberts, DS | 2 |
| Takahashi, K | 1 |
| Mori, T | 1 |
| Takahashi, T | 1 |
| Wallace, DL | 1 |
| O'Toole, RV | 1 |
| Terada, KY | 1 |
| Franklin, EW | 1 |
| Herrer, GW | 1 |
| Goldberg, DA | 1 |
| Hannigan, EV | 1 |
3 trials available for floxuridine and Minimal Disease, Residual